Akers Biosciences Inc (NASDAQ:AKER) saw a large drop in short interest in the month of November. As of November 29th, there was short interest totalling 53,000 shares, a drop of 93.9% from the November 14th total of 875,400 shares. Based on an average daily volume of 41,900 shares, the days-to-cover ratio is presently 1.3 days. Currently, 10.2% of the company’s stock are short sold.
AKER opened at $3.11 on Friday. The business has a 50 day moving average of $2.04 and a 200-day moving average of $0.86. Akers Biosciences has a 52 week low of $2.67 and a 52 week high of $36.96.
Separately, ValuEngine cut Akers Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, November 25th.
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.
Featured Article: How to invest in blue-chip stocks
Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.